Biosimilars and Patents
Leonita Paulraj - Associate, AA Thornton
The majority of the world’s biggest selling medicines can be classified as “biologics” or “biopharmaceuticals”. Such medicines contain one or more biologically active product produced from (or containing components of)...
UK Supreme Court inflicts more patent pain on Warner-Lambert
Eilidh Pugh, Pharmaceutical Patent Attorney, AdamsonJones.
The UK Supreme Court has handed down its much-anticipated decision in WarnerLambert Company LLC v Generics (UK) Ltd t/a Mylan and Actavis. The case is important because it is the...
Patent Protection of Medical Devices – Time for a Rethink?
Christopher Burnett, Patent Attorney, AA Thornton
The duration of patent protection for medical devices is up to twenty years, as for any other type of device. Pharmaceuticals, on the other hand, may be entitled to an...
How intellectual property can help 3D printing support, not harm, medtech
3D printing, or additive manufacturing, is frequently, and rightly, hailed as the next revolution in technology.
Since its inception in 1986, 3D printing has transformed numerous sectors including aviation, manufacturing, and energy, and altered perceptions...
Considering a pharma and bioscience patent? The UK Intellectual Property Office maps out the...
Lawrence Cullen & Laura Starrs, Patent Examining Group Heads, IPO
Managing a patent portfolio requires, among many skills, the ability to anticipate the future. This is especially true in the fields of bioscience and pharma where,...
Patenting aerospace medicines – the final frontier?
Research and development (R&D) into aerospace medicine can be viewed as falling into one of two camps: that aimed at adapting an existing ‘terrestrial’ medicine for use in the aerospace environment; and that which...
Know your third party patent rights
In the competitive world of the biosciences, third party patent rights (TPRs) can stand in the way of a planned course of action, even after significant investment has been made. Knowledge of such rights...
The IP journey and risk mitigation
Paul Storer
Senior Policy Adviser in the Business Support Policy Team at the IPO
Resolving IP disputes can be costly and the Intellectual Property Office continues to seek to reduce costs for businesses, not only in...
Preparations for AI patenting in Europe
The current era of rapid technological development requires industry to be quick to respond to challenges and opportunities, with many choosing to exploit new AI technologies rather than wait to be disrupted by competitors.
Intellectual...
EU-wide IP Expertise is essential to the life science industry post-Brexit
The UK is world-renowned for its progressive life science and healthcare sectors, which are at the forefront of technical innovation, research excellence, and pioneering treatments.
Life science companies, research and development facilities, scientists and academics...
The importance of Intellectual Property strategy; creating a foundation on which to build value...
Dr Emma Longland and Craig Thomson
of HGF writing for the Chartered Institute of Patent Attorneys
Most companies in the Biotech space appreciate the need for patent protection; after all, no company wants to bring...